Precision BioSciences Prices $125 Million Equity and Warrant Financing
+1 new source since this summary was written
Precision BioSciences priced a financing on November 5, 2026, consisting of 10,235,077 common shares at $7.75 each and pre-funded warrants for 5,893,964 shares at $7.749995 per warrant. The transaction is expected to settle on November 6, 2026, provided standard closing requirements are met. Precision plans to use the net proceeds for PBGENE-HBV and PBGENE-DMD development, working capital and other corporate needs.
Why it matters
The financing gives Precision additional funds for its gene-editing programs and corporate operations, while issuing shares and warrants can increase potential equity dilution for existing holders. Completion remains dependent on standard closing requirements.
Key facts
- 1Precision BioSciences expects gross proceeds of approximately $125 million before offering-related deductions. investing.com
- 2The offering includes 10,235,077 common shares priced at $7.75 per share. investing.com
- 3Pre-funded warrants covering 5,893,964 shares are priced at $7.749995 per warrant. investing.com
- 4TD Cowen and Guggenheim Securities are serving as joint book-running managers. investing.com
- 5The company expects the financing to close on or about November 6, 2026, subject to standard closing requirements. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.